Literature DB >> 19681884

Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.

Ali Taher1, Chaim Hershko, Maria Domenica Cappellini.   

Abstract

Thalassaemia intermedia (TI) is a syndrome marked by its diverse underlying genetic basis although its pathophysiology remains unclear, particularly regarding the nature of iron loading and toxicity. It is, however, evident that there are key differences from the extensively studied thalassaemia major (TM) population and caution is required when assessing iron load based on serum ferritin values, as this approach is known to underestimate the true extent of iron loading in patients with TI. Although effective iron chelation therapy has been available for many years, studies in TI-specific populations are rare and evidence suggests that management of iron levels may be less rigorous than in patients with TM and other chronic anaemias. Better understanding of the need to assess and treat iron overload in both transfused and non-transfused TI patients is clearly required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681884     DOI: 10.1111/j.1365-2141.2009.07848.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.

Authors:  J Cusato; S Allegra; D Massano; S De Francia; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2014-10-28       Impact factor: 3.550

3.  Polystyrene microsphere-ferritin conjugates: a robust phantom for correlation of relaxivity and size distribution.

Authors:  Preeti A Sukerkar; Uzma G Rezvi; Keith W Macrenaris; Pinal C Patel; John C Wood; Thomas J Meade
Journal:  Magn Reson Med       Date:  2010-10-28       Impact factor: 4.668

4.  Serum ferritin in thalassemia intermedia.

Authors:  Ravi Shah; Amita Trehan; Reena Das; R K Marwaha
Journal:  Indian J Hematol Blood Transfus       Date:  2013-06-06       Impact factor: 0.900

5.  Gdf15 regulates murine stress erythroid progenitor proliferation and the development of the stress erythropoiesis niche.

Authors:  Siyang Hao; Jie Xiang; Dai-Chen Wu; James W Fraser; Baiye Ruan; Jingwei Cai; Andrew D Patterson; Zhi-Chun Lai; Robert F Paulson
Journal:  Blood Adv       Date:  2019-07-23

6.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.

Authors:  Khaled M Musallam; Maria Domenica Cappellini; John C Wood; Irene Motta; Giovanna Graziadei; Hani Tamim; Ali T Taher
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

Review 7.  Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

Authors:  Wai Cheng Foong; Jacqueline J Ho; C Khai Loh; Vip Viprakasit
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

Review 8.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 9.  Iron homeostasis in the liver.

Authors:  Erik R Anderson; Yatrik M Shah
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

10.  Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.

Authors:  Antonella Nai; Alessia Pagani; Giacomo Mandelli; Maria Rosa Lidonnici; Laura Silvestri; Giuliana Ferrari; Clara Camaschella
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.